Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety, and Tolerability of B2227 and Vraylar® in Participants With Schizophrenia
NCT07722728Phase 3Not yet recruiting
- Sponsor
- Bostal Pharma
- Start
- Aug 2026
- Primary completion
- Aug 2027
01
Overview
A Phase 3 trial of B2227 LAI in schizophrenia, sponsored by Bostal Pharma. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
B2227 LAI
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07722728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07722728.